Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical Business ReviewThe treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Business Review The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere claims first FDA OK in rare kidney disease FSGSNext: Travere Therapeutics gains FDA approval for sparsentan in FSGS Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
